>
Proteomics International Laboratories logo

PIQ - Proteomics International Laboratories Share Price

A$1.22 0.1  10.9%

Last Trade - 7:10am

Sector
Healthcare
Size
Small Cap
Market Cap £70.4m
Enterprise Value £66.3m
Revenue £704k
Position in Universe 811th / 1911
Bullish
Bearish
Unlock PIQ Revenue
Momentum
Relative Strength (%)
1m -5.26%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.61 0.85 0.94 1.20 1.52 1.61 +21.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020,Proteomics International LaboratoriesLtd revenues decreased35% to A$602K. Net loss increased 56% to A$1.9M. Revenuesreflect Revenue Sales of Goods & Services decrease of 38%to A$577K, Interest income decrease of 44% to A$4K. Highernet loss reflects Professional fees increase from A$233K toA$530K (expense), Employment and labour expenses increaseof 27% to A$1.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for PIQ
Graphical History

Revenue

PIQ Revenue Unlock PIQ Revenue

Net Income

PIQ Net Income Unlock PIQ Revenue

Normalised EPS

PIQ Normalised EPS Unlock PIQ Revenue

PE Ratio Range

PIQ PE Ratio Range Unlock PIQ Revenue

Dividend Yield Range

PIQ Dividend Yield Range Unlock PIQ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
PIQ EPS Forecasts Unlock PIQ Revenue
Profile Summary

Proteomics International Laboratories Limited is a biological research and drug discovery company. The Company operates in three business units unified by a technology platform: Analytical services, which includes specialist contract research, analytical testing and consultancy; Diagnostics, which includes biomarkers of disease and personalized medicine, and Therapeutics, which includes peptide drug discovery from venoms. The Company focuses on the PromarkerD, a proteomics-derived predictive and diagnostic test for diabetic kidney disease. The Company focuses on its diagnostics portfolio using the Promarker platform, and is investigating proteins associated with endometriosis, mesothelioma and other conditions. The Company has a therapeutic drug discovery program targeting new analgesic (painkilling) and antibiotic drug compounds. The Company also has a laboratory to analyze the make-up of biosimilar drugs as being like-for-like with the brand name drugs they seek to replace.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated June 9, 2014
Public Since April 16, 2015
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 104,905,875
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PIQ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PIQ
Upcoming Events for PIQ
Frequently Asked Questions for Proteomics International Laboratories
What is the Proteomics International Laboratories share price?

As of 7:10am, shares in Proteomics International Laboratories are trading at A$1.22, giving the company a market capitalisation of £70.4m. This share price information is delayed by 15 minutes.

How has the Proteomics International Laboratories share price performed this year?

Shares in Proteomics International Laboratories are currently trading at A$1.22 and the price has moved by 0.244k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Proteomics International Laboratories price has moved by 0.157k% over the past year.

What are the analyst and broker recommendations for Proteomics International Laboratories?

There are no analysts currently covering Proteomics International Laboratories.

When will Proteomics International Laboratories next release its financial results?

Proteomics International Laboratories is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Proteomics International Laboratories dividend yield?

Proteomics International Laboratories does not currently pay a dividend.

Does Proteomics International Laboratories pay a dividend?

Proteomics International Laboratories does not currently pay a dividend.

When does Proteomics International Laboratories next pay dividends?

Proteomics International Laboratories does not currently pay a dividend.

How do I buy Proteomics International Laboratories shares?

To buy shares in Proteomics International Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Proteomics International Laboratories?

Shares in Proteomics International Laboratories are currently trading at A$1.22, giving the company a market capitalisation of £70.4m.

Where are Proteomics International Laboratories shares listed? Where are Proteomics International Laboratories shares listed?

Here are the trading details for Proteomics International Laboratories:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: PIQ
What kind of share is Proteomics International Laboratories?

Based on an overall assessment of its quality, value and momentum, Proteomics International Laboratories is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Proteomics International Laboratories share price forecast 2021?

We were not able to load any forecast data for Proteomics International Laboratories.

How can I tell whether the Proteomics International Laboratories share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Proteomics International Laboratories. Over the past six months, the relative strength of its shares against the market has been 0.117k%. At the current price of A$1.22, shares in Proteomics International Laboratories are trading at 52.15% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Proteomics International Laboratories PE Ratio?

We were not able to find PE ratio data for Proteomics International Laboratories.

Who are the key directors of Proteomics International Laboratories?

Proteomics International Laboratories's management team is headed by:

Terry Sweet - NEC
Richard Lipscombe - MDR
Karen Logan - SEC
Ian Moore - NED
Paul Edward House - NED
Who are the major shareholders of Proteomics International Laboratories?

Here are the top five shareholders of Proteomics International Laboratories based on the size of their shareholding:

Lipscombe (Richard John) Individual Investor
Percentage owned: 18.11% (19.0m shares)
Dunlop (John Sutherland R) Individual Investor
Percentage owned: 3.66% (3.86m shares)
Xylo Pty. Ltd. Corporation
Percentage owned: 2.86% (3.00m shares)
Sweet (Terry) Individual Investor
Percentage owned: 2.23% (2.35m shares)
Randolph Resources Pty. Ltd. Corporation
Percentage owned: 1.85% (1.95m shares)
Similar to PIQ
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.